Investigating how hydroxychloroquine may prevent autoimmune diseases
Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLE
This study is looking at how the immune system works in people with early signs of autoimmune diseases and whether a medication called hydroxychloroquine can help stop these early signs from turning into serious conditions like type 1 diabetes or lupus, by analyzing blood samples from participants at different stages of their health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11091902 on NIH RePORTER |
What this research studies
This research focuses on understanding the immune mechanisms that lead to autoimmune diseases by analyzing serum samples from clinical trials. It specifically examines how hydroxychloroquine (HCQ) may help prevent the progression from sub-clinical autoimmunity, indicated by the presence of autoantibodies, to full-blown autoimmune diseases like type 1 diabetes, systemic lupus erythematosus, and rheumatoid arthritis. By profiling serum proteins from participants at different stages of their disease, the study aims to identify common features that could inform future treatments. The research utilizes advanced proteomic analysis techniques to gather comprehensive data on immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a high risk of developing autoimmune diseases, particularly those with positive autoantibody tests.
Not a fit: Patients who are already diagnosed with advanced autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention strategies for autoimmune diseases, potentially benefiting many patients at risk.
How similar studies have performed: Previous research has shown promise in using similar proteomic approaches to understand autoimmune diseases, indicating potential for success in this study.
Where this research is happening
Seattle, United States
- Benaroya Research Inst at Virginia Mason — Seattle, United States (Active)
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.